Researchers have unraveled new insights into the way cells leverage G-protein-coupled receptors (GPCRs) and their cellular waste disposal systems to control inflammation. The findings suggest some existing cancer drugs that inhibit these cellular activities might be repurposed to treat vascular inflammation, which occurs when artery-blocking plaques form in atherosclerosis.